SyGoBioClin: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
SyGoBioClin
Largest movements
- Cash +€18,912
up €18,912 (+9.2%), from €206,384 to €225,296
mainly Other debts (+€209,273) and Net result for the year (+€41,654)
- Receivables within one year +€6,736
new in 2025: €6,736
- Tangible fixed assets -€2,661
down €2,661 (-45.3%), from €5,877 to €3,216
- Other debts +€209,273
up €209,273 (+1,552%), from €13,485 to €222,758
- Profit (loss) carried forward -€163,458
down €163,458 (-100%), from €163,458 to €0
- Tax, wage and social debts -€22,790
down €22,790 (-82.3%), from €27,679 to €4,889
- Gross operating margin -€47,537
down €47,537 (-45.6%), from €104,161 to €56,624
- Taxes -€11,432
down €11,432 (-50.4%), from €22,696 to €11,264
- Financial charges -€1,045
down €1,045 (-93.7%), from €1,115 to €70
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €212,261 | €235,248 | +€22,988 | +10.8% |
| Fixed assets | 21/28 | €5,877 | €3,216 | -€2,661 | -45.3% |
| Tangible fixed assets | 22/27 | €5,877 | €3,216 | -€2,661 | -45.3% |
| Furniture and vehicles | 24 | €5,877 | €3,216 | -€2,661 | -45.3% |
| Current assets | 29/58 | €206,384 | €232,032 | +€25,649 | +12.4% |
| Amounts receivable within one year | 40/41 | - | €6,736 | +€6,736 | |
| Other amounts receivable | 41 | - | €6,736 | +€6,736 | |
| Cash at bank and in hand | 54/58 | €206,384 | €225,296 | +€18,912 | +9.2% |
| Total equity and liabilities | 10/49 | €212,261 | €235,248 | +€22,988 | +10.8% |
| Equity | 10/15 | €168,958 | €5,500 | -€163,458 | -96.7% |
| Contributions | 10/11 | €5,500 | €5,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | €163,458 | €0 | -€163,458 | -100% |
| Amounts payable | 17/49 | €43,302 | €229,748 | +€186,446 | +431% |
| Amounts payable within one year | 42/48 | €41,201 | €227,647 | +€186,446 | +453% |
| Trade debts | 44 | €37 | €0 | -€37 | -100% |
| Suppliers | 440/4 | €37 | €0 | -€37 | -100% |
| Taxes, remuneration and social security | 45 | €27,679 | €4,889 | -€22,790 | -82.3% |
| Taxes | 450/3 | €27,679 | €4,889 | -€22,790 | -82.3% |
| Other amounts payable | 47/48 | €13,485 | €222,758 | +€209,273 | +1,552% |
| Accrued charges and deferred income | 492/3 | €2,101 | €2,101 | = | 0.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,281 | €2,661 | +€380 | +16.7% |
| Other operating charges | 640/8 | €451 | €976 | +€525 | +116% |
| Gross operating margin | 9900 | €104,161 | €56,624 | -€47,537 | -45.6% |
| Operating profit (loss) | 9901 | €101,429 | €52,987 | -€48,442 | -47.8% |
| Financial income | 75/76B | - | €0 | +€0 | |
| Recurring financial income | 75 | - | €0 | +€0 | |
| Financial charges | 65/66B | €1,115 | €70 | -€1,045 | -93.7% |
| Recurring financial charges | 65 | €1,115 | €70 | -€1,045 | -93.7% |
| Profit (loss) for the period before taxes | 9903 | €100,314 | €52,917 | -€47,397 | -47.2% |
| Income taxes | 67/77 | €22,696 | €11,264 | -€11,432 | -50.4% |
| Profit (loss) for the period | 9904 | €77,618 | €41,654 | -€35,965 | -46.3% |
| Profit (loss) for the period to be appropriated | 9905 | €77,618 | €41,654 | -€35,965 | -46.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 21 October 2026 via checked.be.